Glioblastoma (GBM) is the most aggressive form of primary brain tumour, with dismal patient
outcome. Treatment failure is associated with intrinsic or acquired apoptosis resistance and …

The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) shows a
promising therapeutic potential in cancer treatment as it exclusively causes apoptosis in a …

The apoptotic ligand TRAIL is believed to have promise as a cancer gene therapy, yet many
types of cancer, including gliomas, have exhibited resistance to TRAIL-induced apoptosis …

Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induced apoptosis
specifically in tumor cells. However, with approximately half of all known tumor lines being …

The proapoptotic cytokine tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)
is being evaluated presently as a selective anticancer agent, but its limited effects against …

Despite advances in standard therapies, the survival of glioblastoma multiforme (GBM)
patients has not improved. Limitations to successful translation of new therapies include …

The cytotoxic effect of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is
limited in many glioma cell lines. However, treatment with TRAIL in combination with …

TNF‐related apoptosis‐inducing ligand (TRAIL) induces apoptosis selectively in cancer
cells. For melanoma, the targeting of TRAIL signaling appears highly attractive, due to …

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) has been increasingly
studied for the treatment of gliomas. TRAIL has the ability to specifically target cancer cells …

The major aim of this study was to develop novel therapeutic approaches to potentiate and
reactivate apoptosis induced by TNF-Related Apoptosis Inducing Ligand (TRAIL) in …